Oniria Therapeutics, UB spin-off, named one of the ten most disruptive Catalan companies
Oniria Therapeutics, a spin-off from the University of Barcelona, has been named one of the ten most disruptive Catalan companies in 2024. The biopharmaceutical company focuses on the development of targeted therapies to eliminate persistent tumor cells in conventional treatments and responsible for the progression of patients to deadly stages of cancer. Oniria is also a spin-off of the Vall d’Hebron Institute of Oncology (VHIO), and of the Catalan Institute for Research and Advanced Studies (ICREA).
ACCIÓ – the agency for the competitiveness of the company – of the Generalitat de Catalunya, as part of the Exponential Day event, has awarded the ‘Catalonia Exponential Leaders’ to ten companies for their ability to generate an impact positive in society, for its commitment to generate a differential value, the business culture and the possibilities of exponential growth.
The companies selected by ACCIÓ are specialized in sectors and areas such as health and life sciences, mobility, energy or food. These are companies that have applied innovative and disruptive technologies in their business models, such as artificial intelligence, robotics, blockchain, the use of batteries, or elements of the blue economy, among others.
The recognized companies are: Blindstairs, Suara Cooperativa, Magnetika, Navozyme, Ocean Ecostructures, Oniria Therapeutics, Scent XP, Cuatrecasas, Timeisbrain and Uobo.